Størling Louise, Villadsen Gerda Elisabeth, Krogh Klaus, Vestergaard Peter
Klinisk Farmakologisk Afdeling, Bispebjerg -Hospital, Bispebjerg Bakke 23, 2400 København NV. E-mail:
Ugeskr Laeger. 2014 Jul 21;176(30).
This case report shows how denosumab apparently treated bisphosphonate-refractory hypercalcaemia caused by a neuroendocrine tumour of the pancreas in a 48-year-old woman. We cannot eliminate the possibility that the patient's DOTATOC-treatment contributed to the decline in plasma calcium concentration. Preliminary results from a recent large, clinical trial, suggest that denosumab is a more potent treatment of malignancy-associated hypercalcaemia than bisphosphonates.
本病例报告展示了地诺单抗如何明显治疗了一名48岁女性因胰腺神经内分泌肿瘤引起的双膦酸盐难治性高钙血症。我们无法排除患者的DOTATOC治疗导致血浆钙浓度下降的可能性。最近一项大型临床试验的初步结果表明，与双膦酸盐相比，地诺单抗是治疗恶性肿瘤相关性高钙血症更有效的药物。
